Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 2 |
2011 | 1 |
2012 | 2 |
2013 | 2 |
2020 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
zhenxian du[Author]
(40 results)?
Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.
Bioorg Med Chem Lett. 2013 Sep 15;23(18):5070-6. doi: 10.1016/j.bmcl.2013.07.032. Epub 2013 Jul 25.
Bioorg Med Chem Lett. 2013.
PMID: 23937981
Elesclomol induces cancer cell apoptosis through oxidative stress.
Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, Du Z, Barsoum J, Bertin J.
Kirshner JR, et al. Among authors: du z.
Mol Cancer Ther. 2008 Aug;7(8):2319-27. doi: 10.1158/1535-7163.MCT-08-0298.
Mol Cancer Ther. 2008.
PMID: 18723479
Item in Clipboard
UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study.
Wang H, Wang T, Wang Z, Du Z, Zhao Q, Jiang J, Hu P.
Wang H, et al. Among authors: du z.
Bioanalysis. 2020 Mar;12(6):367-378. doi: 10.4155/bio-2020-0008. Epub 2020 Apr 14.
Bioanalysis. 2020.
PMID: 32285686
Item in Clipboard
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
Yang M, Shan B, Li Q, Song X, Cai J, Deng J, Zhang L, Du Z, Lu J, Chen T, Wery JP, Chen Y, Li Q.
Yang M, et al. Among authors: du z.
Int J Cancer. 2013 Jan 15;132(2):E74-84. doi: 10.1002/ijc.27813. Epub 2012 Oct 3.
Int J Cancer. 2013.
PMID: 22948846
Free article.
Item in Clipboard
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C.
Lin TY, et al. Among authors: du z.
Exp Hematol. 2008 Oct;36(10):1266-77. doi: 10.1016/j.exphem.2008.05.001. Epub 2008 Jul 26.
Exp Hematol. 2008.
PMID: 18657349
Free PMC article.
Item in Clipboard
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.
Ying W, et al. Among authors: du z.
Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.
Mol Cancer Ther. 2012.
PMID: 22144665
Item in Clipboard
Cite
Cite